The estimated Net Worth of Yarlagadda S Babu is at least $5.65 Million dollars as of 14 November 2022. Yarlagadda Babu owns over 100,000 units of Biocryst Pharmaceuticals stock worth over $2,551,333 and over the last 16 years he sold BCRX stock worth over $2,019,161. In addition, he makes $1,083,310 as Senior Vice President - Drug Discovery at Biocryst Pharmaceuticals.
Yarlagadda has made over 21 trades of the Biocryst Pharmaceuticals stock since 2009, according to the Form 4 filled with the SEC. Most recently he exercised 100,000 units of BCRX stock worth $142,000 on 14 November 2022.
The largest trade he's ever made was exercising 100,000 units of Biocryst Pharmaceuticals stock on 14 November 2022 worth over $142,000. On average, Yarlagadda trades about 10,476 units every 81 days since 2009. As of 14 November 2022 he still owns at least 330,056 units of Biocryst Pharmaceuticals stock.
You can see the complete history of Yarlagadda Babu stock trades at the bottom of the page.
Dr. Yarlagadda S. Babu Ph.D. serves as Senior Vice President - Drug Discovery of the Company. Dr. Babu joined BioCryst in 1988 and was BioCryst’s first full-time employee. Dr. Babu has served as the Company’s Vice President — Drug Discovery since 1992. In October of 2013, Dr. Babu’s title was changed to Senior Vice President of Drug Discovery. Prior to joining BioCryst, he served five years on the biochemistry faculty at the University of Alabama at Birmingham (“UAB”). Dr. Babu obtained his Ph.D. from the Indian Institute of Science, Bangalore and spent three years in the Laboratory of Molecular Biophysics at the University of Oxford, U.K. before joining UAB. He has over 70 publications in peer-reviewed journals, and a number of issued and pending patents to his credit.
As the Senior Vice President - Drug Discovery of Biocryst Pharmaceuticals, the total compensation of Yarlagadda Babu at Biocryst Pharmaceuticals is $1,083,310. There are 4 executives at Biocryst Pharmaceuticals getting paid more, with Jon Stonehouse having the highest compensation of $2,284,300.
Yarlagadda Babu is 67, he's been the Senior Vice President - Drug Discovery of Biocryst Pharmaceuticals since 2013. There are 5 older and 17 younger executives at Biocryst Pharmaceuticals. The oldest executive at Biocryst Pharmaceuticals Inc. is Robert Ingram, 77, who is the Independent Chairman of the Board.
Yarlagadda's mailing address filed with the SEC is 4505 EMPEROR BLVD., SUITE 200, DURHAM, NC, 27703.
Over the last 24 years, insiders at Biocryst Pharmaceuticals have traded over $76,362,383 worth of Biocryst Pharmaceuticals stock and bought 4,042,003 units worth $20,848,654 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Brothers Life Sciences Capi..., and Carl L Gordon. On average, Biocryst Pharmaceuticals executives and independent directors trade stock every 31 days with the average trade being worth of $542,329. The most recent stock trade was executed by Amy E Mc Kee on 24 June 2024, trading 8,600 units of BCRX stock currently worth $54,352.
biocryst pharmaceuticals, a biotechnology company, designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and rare diseases. founded in 1986, biocryst has more than 50 employees and is experiencing continued growth. the company’s headquarters are located in research triangle park, north carolina and its discovery center of excellence is in birmingham, alabama. with expertise in drug discovery, clinical development, regulatory affairs and product commercialization, we continue to advance our clinical programs and to generate new compounds from our own discovery engine. we are proud of our culture of engagement and accountability that rewards people for innovative thinking and achievement of key objectives. the commitment of biocryst remains unchanged. we continue to be passionate about developing and marketing novel therapeutics for patients with rare and serious diseases.
Biocryst Pharmaceuticals executives and other stock owners filed with the SEC include: